City of Hope National Medical Center
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From City of Hope National Medical Center
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
Cancer deals involve City of Hope/Chimeric, CARISMA/NYU, Sorrento/Mayo Clinic, Rain/Drexel, Diaprost/Memorial Sloan Kettering, Alkido/University of Kentucky. Plus, research collaborations in brief.
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
Private Company Edition: Immunocore’s $130m round kicked off a series of $100m-plus venture capital deals, including financings for Xilio, Akouos and Pliant. Also, VC investment in cell and gene therapies surged in 2019 and MPM launched two funds with $126 for early cancer research.
- Academic and Research Institutions
- Other Names / Subsidiaries
- City of Hope Obligated Group